Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM1PM2PP3
The NM_007294.4(BRCA1):āc.269T>Cā(p.Ile90Thr) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I90F) has been classified as Uncertain significance.
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Verdict is Uncertain_significance. Variant got 5 ACMG points.
PM1
In a hotspot region, there are 4 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 6 benign, 17 uncertain in NM_007294.4
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.789
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:1Other:1
not provided, no classification provided
in vitro
Brotman Baty Institute, University of Washington
-
- -
Uncertain significance, no assertion criteria provided
clinical testing
Breast Cancer Information Core (BIC) (BRCA1)
Apr 06, 1999
- -
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
May 19, 2016
Variant summary: The BRCA1 c.269T>C (p.Ile90Thr) variant involves the alteration of a conserved nucleotide and results in a replacement of a medium size and hydrophobic Isoleucine (I) with a medium size and polar Threonine (T). Residues 8-22 and 81-96 of BRCA1 protein form antiparallel alpha-helices flanking the central RING domain (residues 23-76), and are thought to be critical for the proper association of the BRCA1 and BARD1 proteins (Brzovic_Nat Struct Biol_2001). Consistently, 4/5 in silico tools predict the variant to be deleterious. 4/5 in silico tools predict a damaging outcome. This variant is absent in 121322 control chromosomes. It was reported once by the BIC database in one individual from an HBOC family however, without strong evidence for pathogenicity. Functional studies demonstrated the variant to be proficient in BARD1 and UbcH5a binding and to slightly decrease E3 activity of BRCA1. Most importantly, the variant was shown not to have a significant impact on homology directed repair activity of BRCA1 which is essential for its tumor suppressing function. The functional studies indicate the variant to be in the neutral spectrum, however, due to lack of stronger clinical information about variant carries, the variant was classified as a variant of uncertain significance (VUS) until additional information becomes available. -
Loss of stability (P = 0.0278);Loss of stability (P = 0.0278);Loss of stability (P = 0.0278);Loss of stability (P = 0.0278);.;Loss of stability (P = 0.0278);.;Loss of stability (P = 0.0278);.;.;Loss of stability (P = 0.0278);Loss of stability (P = 0.0278);Loss of stability (P = 0.0278);.;Loss of stability (P = 0.0278);Loss of stability (P = 0.0278);.;.;